Lyras Pharma successfully completes pharma supplier inspection

Lyras Pharma successfully completes independent pharma supplier inspection

We are proud to announce that Lyras Pharma has successfully completed a supplier inspection initiated by a global pharmaceutical company. For our team, the result is an important recognition of the organisation, processes and documentation behind our Raslysation™ technology.

Bringing technology into the pharmaceutical industry takes more than a strong idea. Customers need to trust not only the technology, but also the people and organisation responsible for delivering it.

That trust is built through robust processes, consistent quality assurance and the ability to demonstrate that every requirement has been met.

This is why successfully completing the independent supplier inspection is such an important milestone for us. It reflects the commitment and attention to quality demonstrated every day by colleagues across Lyras Pharma and the wider Lyras Group.

The inspection was initiated by a global pharmaceutical company and conducted by Aliscon, an independent specialist with extensive experience in quality assurance and documentation within the pharmaceutical and food industries.

The assessment covered our documentation, internal processes, production facilities and quality assurance practices.

What the pharma supplier inspection assessed

Christian Willemoes Larsen, Director at Aliscon, led the inspection and met the people responsible for turning our quality requirements into daily practice.

“What stood out was the combination of a strong technology and a well-run organisation behind it. The production facilities were exceptionally clean, organised and well maintained, the internal processes were under control, and quality was clearly reflected in the way the company operates.”

For us, this observation is particularly meaningful. The inspection was not only an assessment of what we produce, but also of how we work together as an organisation.

When a technology supplier enters the pharmaceutical industry, the technology itself is only the starting point. The entire delivery must meet the required standards, from engineering and manufacturing to testing, verification, and documentation.

As Christian Willemoes Larsen explains:

“A good invention is the starting point, but that alone does not make a company pharma compliant. I look at the quality of the entire delivery. Is the technology engineered and manufactured properly? Are the internal processes under control? And can the company document and demonstrate that the requirements have actually been met? That is what creates credibility.”

Quality begins long before the inspection

Quality assurance is not a final check performed when a project is complete. It begins much earlier, with a clear understanding of customer, contractual, and regulatory requirements.

Potential gaps must be identified, requirements clarified, and the right processes, testing, and documentation established from the outset. This is how quality becomes part of the delivery rather than something added at the end.

“The earlier quality requirements are addressed, the better. Quality assurance is not simply about checking documentation at the end of a project. It is about understanding and interpreting the requirements, identifying gaps, clarifying requirements where necessary, and making sure that quality can actually be demonstrated through the right processes, testing, and documentation.”

The objective is not documentation for its own sake. It is to make quality visible, traceable and demonstrable, for our customers and for everyone involved in delivering the technology.

During the inspection, Aliscon found a clear connection between the requirements being assessed and what our team could demonstrate in practice.

“What gave me confidence was the consistency between the requirements we were assessing against and what Lyras could actually demonstrate. The processes, documentation and way of working supported each other. And importantly, it did not feel like something put in place for the inspection. You could see that quality was embedded in the daily operation and reflected in the culture across the organisation.”

That assessment is a recognition of the work our colleagues do every day. Quality is not treated as a separate activity at Lyras Pharma. It is embedded in the way we develop, manufacture, document, and deliver our solutions.

An important milestone for Raslysation™ in pharma

The successful supplier inspection demonstrates that Lyras Pharma has the organisation and quality processes required to support the application of the technology within the pharmaceutical industry.

For Nete Zarp Nielsen, COO and EVP at Lyras, the result is both a professional achievement and a proud moment for the organisation.

“For pharmaceutical customers, confidence in the supplier is just as important as confidence in the technology. We are proud to have demonstrated the quality of the organisation, processes and documentation behind our technology.”

The successful inspection marks an important step in our pharmaceutical journey. It shows that we are not only developing strong technology, but also building the organisation, culture, and quality framework needed to deliver it responsibly and consistently.

Most importantly, it gives our pharmaceutical customers greater confidence in the people, processes and documentation behind Raslysation™.

Because in pharma, quality is not something you claim. It is something you demonstrate every day.

Learn more about the Raslysation technology